wwaswas:
biggest problem is that pharma won’t invest because there’s a small market for this type of antibiotic and governments don’t see it as their job to develop new drugs.
Bolleaux.
There is an excellent market for these drugs, it’s just that they take lots of research and many years to develop. And research is difficult. Yes, current antibiotics are cheap but that’s because they’ve been around for years.
Here’s a press release from a small Liverpool-based biotech, RedX:
Redx is a good example of the role these organisations can play in tackling this issue. Later this year, we will open a new £10.8 million research and development centre focused on anti-viral and anti-bacterial drugs. One of our key focus areas will be developing drugs to combat resistance to antibiotics. Importantly, this work is supported by the Government through a grant from the Regional Growth Fund of £4.7 million.
Several of the big pharma companies are also working on novel antibiotics, because they see a future need and future profit. The typical cost of getting a new drug to market these days, including the cost of the failed programmes, is somewhere north of £3 billion.